State Street Reports 4.1% Ironwood Stake As Drugmaker Raises Its Annual Revenue Outlook
The holding dates to September 30, and State Street certified it was not seeking to influence the drugmaker's control.
State Street reported a 4.1% stake in Ironwood Pharmaceuticals, which develops and sells medicines for gastrointestinal and rare diseases, in a passive ownership disclosure filed Tuesday. The position totaled 6,723,774 common shares as of September 30, rather than measuring a purchase on the filing date.
A Passive Position With Voting Power
State Street had shared voting power over 6,516,093 shares and shared authority to dispose of the full holding. It reported no sole voting or disposal power.
State Street certified that the securities were obtained and held as part of its ordinary business, not for the purpose or effect of changing or influencing Ironwood's control. The percentage applies to Ironwood's common-stock class on the disclosure's beneficial-ownership basis.
Linzess Supports A Higher Forecast
Ironwood's earnings report paired a quarterly revenue miss against the Zacks consensus estimate with a higher revenue forecast for 2026. The company now expects $485 million-$510 million, compared with its earlier $460 million-$485 million range, and projects higher U.S. Linzess sales.
The Linzess collaboration with AbbVie contributed $129.9 million to Ironwood's third-quarter revenue of $133 million. Ironwood and AbbVie divide U.S. linaclotide net profits and losses equally; Ironwood also receives royalties from overseas partners.
Linzess treats irritable bowel syndrome with constipation and other constipation conditions in adults and certain pediatric patients. Linaclotide also sells under the Constella name in overseas markets, including Canada, Mexico, Japan, China and certain European countries. The U.S. supplied 97.7% of Ironwood's revenue in 2025.
Shares rose 6.9% after the earnings report and outlook increase, taking their year-to-date gain to 19.6%, against a 0.8% industry decline. Ironwood's market value was $775 million as of 8:44 a.m. ET Tuesday.
Alongside its commercial linaclotide business, Ironwood is developing apraglutide for short bowel syndrome patients who rely on intravenous nutrition or fluid support.
Sources
- SCHEDULE 13G — STATE STREET CORPORATION re: IRONWOOD PHARMACEUTICALS INC (IRWD) — SEC EDGAR
- IRWD Q3 Earnings Beat, Revenues Miss, 2026 View Raised, Stock Up — Yahoo Finance